Abstract Our aim was to study the effect of a mucosal protective agent, rebamipide, on the colonic barrier and the immune response in colitis-prone interleukin-10-deficient (IL-10 − / − ) C57BL/6 mice infected with Helicobacter hepaticus. After sacrifice, in all mice, control, or previously infected with H. hepaticus, or previously infected and treated with rebamipide enema, a histological examination of colonic samples was performed, intestinal permeability was studied in Ussing chamber, and mesenteric lymph node proliferation and cytokine secretion were measured. Mice treated with rebamipide presented a reinforcement of the distal colonic epithelial barrier, an increase of mesenteric lymph node cells proliferation, and of IFNγ and IL-12 secretion. These results indicate that in IL-10 − / − mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells. These properties could be helpful in the management of some inflammatory bowel diseases.
Introduction
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), have multifactorial etiologies involving genetic, environmental, and immunological factors. One of the constant features in IBD is the increase in intestinal permeability [1, 2] . Under normal conditions, the intestinal epithelium forms a barrier that simultaneously regulates the absorption of nutrients and water and prevents the uptake of bacteria and bacterial products from the intestinal lumen. An impaired intestinal barrier function is observed in patients with CD [3, 4] but also in healthy relatives of these patients [5] . The unrestricted passage of bacterial antigens from the intestinal lumen may induce the chronic activation of mucosal immune cells, a critical component of the inflammatory process associated with IBD.
Current treatment of IBD has focused on drugs able to decrease inflammation but the question of limiting antigen access to the submucosa by reinforcing the epithelial barrier has not been addressed. Rebamipide is a mucosal protective agent which, in addition to stimulating the production of endogenous prostaglandins in the gastric mucosa and improving ulcer healing [6] , exerts a positive effect on the gastric barrier function. It reinforces the barrier's integrity in basal and inflammatory conditions and it inhibits the increase in macromolecular transepithelial transport induced by Helicobacter pylori [7, 8] . Experimental data have shown that rebamipide can prevent dextran sulfate sodium-induced colitis in rats [9] . In addition, in a human case report, rebamipide exhibited a beneficial effect on a proctitis type of ulcerative colitis [10] .
Murine models of enterocolitis mimicking IBD have been described [11, 12] . Interleukin-10-deficient (IL-10 − / − ) mice infected with H. hepaticus have been shown to develop a moderate to severe inflammation of the large bowel [13] . We hypothesised that in this model of colitis the reinforcement of barrier function and modulation of the intestinal mucosal immune system responses to luminal antigens would be a good therapeutic approach. Therefore, our aim was to study the effect of rebamipide on intestinal permeability and immune response in IL-10 − / − mice infected with H. hepaticus.
Materials and methods

Experimental protocol
Forty female IL-10-deficient C57BL/6 mice (B6.129P2-IL10tm1Cgm/Crl) obtained from Charles River Laboratories, L'Arbresle, France (aged 5 weeks at the beginning of the experimental protocol) were used in this study. They were housed 12 per cage at 20
• C under specific pathogen-free conditions for 2 weeks and then shifted to conventional litter and to a standard non-sterile diet.
Altogether, four groups of mice were studied: Group I = Control group (n = 12): IL-10-deficient non-infected mice, Group II = Infected group (n = 12): IL-10-deficient mice infected with H. hepaticus (strain CCUG 33637, ATCC 51448) by three oral gavages with 2 × 10 9 CFU in 500 µl at the age of 5 weeks, Group III = Rebamipide group (n = 12): IL-10-deficient mice infected with H. hepaticus and then, starting from 1 week after infection, treated daily with rebamipide enema (300 µg of rebamipide in 100 µl of carboxy-methyl cellulose used as a vehicle) for 9 weeks; Group IV = Placebo group (n = 4): IL-10-deficient infected mice, receiving rectally 100 µl of the vehicle carboxy-methyl cellulose for 9 weeks instead of rebamipide enema.
Helicobacter hepaticus infection was confirmed by seminested PCR in stools. After DNA extraction from the fecal samples using the QIAamp DNA stool mini kit (Qiagen) according to the manufacturer's instructions, a PCR was performed using primers F 2 16S and R 4 16S, detecting conserved bacterial 16S ribosomal DNA [14] . These two oligonucleotides produced an amplified product of 1.490 pb. Then 2.5 µl of the fecal DNA preparation was added to a 25-µl (final volume) reaction mixture containing 1X reaction buffer (with 15 mM MgCl 2 ), 0.5 µM each of the two primers, 200 µM each deoxynucleotide, 0.1 µg of bovine serum albumin per µl and 0.025 U/µl of Taq polymerase (Promega, Charbonnières les Bains, France). The following conditions were used for amplification: an initial denaturation at 94
• C for 5 min was followed by 40 cycles (denaturation at 94
• C for 30 s, annealing at 55
• C for 30 s, elongation at 72
• C for 1 min and 20 s) and a final elongation at 72
• C for 7 min. After purification with Sephacryl S-400 highresolution (Amersham Biosciences, Saclay, France) column, a second set of primers was used for the amplification of a Helicobacter spp.-specific 16S ribosomal DNA fragment. These two oligonucleotides, 5 GCTATGACGGGTATCC3 (C 97 ) and 5 GATTTTACCCCTACACCA3 (C 98 ), produced an amplified product of 398 pb. The reaction mixture was the same as this used for the first amplification but without bovine serum albumin. After a denaturation at 94
• C for 5 min, 40 cycles (denaturation at 94
• C for 1 min, annealing at 54
• C for 1 min and elongation at 72
• C for 30 s) and a last elongation at 72
• C for 7 min were performed. PCR was still positive in all infected mice 4 weeks after infection.
Throughout the protocol, the mice were weighed twice a week and their general behavior was recorded. The experiments were conducted in accordance with the ethical guidelines of the French Veterinary Department.
Clinical and histological examination
At the end of the treatment protocol, the mice (aged 16 weeks) were sacrificed, and MLN and the entire colons were obtained. Proximal (caecum) and distal colonic samples were fixed in 4% formaldehyde for histologic examination while other fragments were opened along the mesenteric border and used to study permeability in Ussing chambers.
Microscopic score
Fixed tissues were embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin. Sections were examined blindly by a single pathologist (A.R.). Results were expressed using a histological index ranging from 0 to 4 as previously described [15] . This index is based on the degree of epithelial layer erosion, goblet cell depletion, and inflammatory cell infiltrate [0 = normal; 1 = minimal evidence of inflammatory infiltrate; 2 = significant evidence of inflammatory infiltrate (cryptitis, crypt abscesses); 3 = significant evidence of inflammatory infiltrate with goblet cell depletion; 4 = significant evidence of inflammatory infiltrate with erosion of the mucosa].
Epithelial barrier of the colonic mucosa
One caecal fragment and one distal colonic fragment from each mouse were laid on a Millipore filter (8 µm pores) and mounted as flat sheets in Ussing chambers with an exposed surface area of 0.2 cm 2 . They were bathed on both sides with 1.5 mL of Ringer's solution containing 5 mM mannitol, which was continuously thermostated, circulated, oxygenated, and maintained at pH 7.4 with 5% CO 2 /95% O 2 . The mucosal and serosal bathing solutions were connected via agar bridges to calomel electrodes for measurement of the transepithelial potential difference (PD) and to Ag-AgCl electrodes for current ( I) application. The tissues were kept under open-circuit conditions and electrical measurements were performed using a DVC 1,000-V/current clamp (World Precision Instruments, Aston, U.K.). The tissues were regularly clamped at 1 mV to measure the I and calculate the electrical resistance (R) according to Ohm's law (PD = R × I).
Horseradish peroxidase (HRP, MW 40 kDa) was used as a soluble protein marker of the transcellular transport pathway (transcytosis). Mannitol was used as a small molecular tracer (MW 182 Da) of the paracellular pathway. HRP (0.4 mg/ml), 3 H-HRP (37 kBq/ml) and 14 C-mannitol (12.2 kBq/ml) were simultaneously added to the mucosal compartment bathing intestinal fragments. Samples (800 µl) were taken from the serosal compartment at 10, 30, 50, 70, 90 and 110 min and replaced by fresh Ringer's solution. Intact HRP fluxes from the mucosal to the serosal compartment (JHRPi) were determined by enzymatic assay [16] on 200 µl of serosal samples. Total HRP fluxes (intact + degraded = 3 H-equivalent HRP fluxes) and 14 C-mannitol fluxes were assessed on 500 µl serosal samples by counting the 3 H and 14 C radioactivity, respectively, using liquid scintillation photometry (Kontron, betamatic) after double-labeling correction. Degraded HRP fluxes were calculated as 3 H-equivalent HRP fluxes minus intact HRP fluxes. Mean steady-state fluxes obtained from 50 to 110 min are presented in Fig. 3 .
Activation status of mesenteric lymph node cells
Mesenteric lymph nodes were collected at sacrifice and single-cell suspensions were prepared in Cerottini culture medium (DMEM glutamax supplemented with 8% heatinactivated fetal calf serum, asparagine 36 mg/l, arginine 116 mg/l, folic acid 10 mg/l, HEPES 1g/l, β-mercaptoethanol 0.05 mM, penicillin 100 U/ml, streptomycin 100 µg/ml, fungizone 1 µg/ml). Generally, the total cell count was about 20 × 10 6 cells/mouse, which was adjusted to 2 × 10 6 cells /ml in the culture medium.
Lymphocyte stimulation test: 3 H-thymidine incorporation
Basal and stimulated cell proliferation was analyzed using 3 H-thymidine incorporation. Cells were seeded in 96-well culture microplates at 4 × 10 5 cells/well (180 µl) and were stimulated or not in duplicate with 20 µl of soluble extract of E. coli or H. hepaticus, at the final concentration of 1 and 3 µg/ml, respectively. Soluble E. coli extract was prepared from cultures of E. coli isolated from human flora. The bacteria were harvested and washed thoroughly in PBS, and their lysis was performed by sonication at 4
• C. Cell debris was removed by centrifugation at 8,000 × g for 30 min at 4
• C, and the supernatant was sterile filtered. Its protein content, measured by the Bradford assay (Pierce, France), was 1.2 mg/ml. LPS concentration of this extract was measured using the Limulus amebocyte lysate (Charles River Endosafe, Charleston, VA, USA). The soluble extract contained 8.6 µg/ml of LPS, leading to the final concentration of 86 ng/ml in culture wells. Soluble H. hepaticus extract was prepared from H. hepaticus strain cultures according to the same protocol. There was no detectable LPS in this extract ( < 80 pg/ml). After a 72-h incubation in the presence of soluble E. coli or H. hepaticus, [methyl-
3 H] thymidine (15 kBq/well) was added. 3 H-labelled DNA was extracted 18 h later using a cell harvester (Inotech, Perkin-Elmer). Filters were counted using a 1450 Microbeta Wallac Trilux microplate reader (PerkinElmer Life Sciences, Paris, France). Results are expressed as both counts-per-minute (cpm)/well and as stimulation index (SI), i.e., cpm ratio (stimulated cells/non-stimulated cells).
Cytokine secretion: ELISA and flow cytometry ELISA: MLN cells were also seeded on 24-well culture plates (approximately 2 × 10 6 cells/well) in 1 ml of Cerottini culture medium with and without stimulation by soluble E. coli (1 µg/ml), and H. hepaticus (1 µg/ml) in duplicate. After 72 h, supernatants were collected and frozen at -20
• C until assayed. Four cytokines were assayed: IFNγ , TNFα, IL4 and IL12 using duoset ELISA kits (R&D, Abingdon, UK).
Flow cytometry: IFNγ secretion by MLN cells in basal conditions without stimulation was assessed by flow cytometry using a mouse IFNγ secretion assay (Miltenyi Biotec). MLN samples were seeded on 24-well culture plates (10 6 cells/well) in 1 ml of RPMI containing 5% mouse serum for 16 h. MLN cells were washed in cold buffer, capture antibody against IFNγ /CD45 was added for 5 min on ice, and then the samples were incubated for 45 min at 37
• C under slow continuous rotation to allow cytokine secretion. The samples were washed and treated with anti-IFNγ APCconjugated detection antibodies for 10 min on ice. The cells were counterstained with monoclonal antibody against CD3-PE, CD4-FITC or CD3-PE, CD8-FITC.
Activation markers on T cells CD44 and CD62L markers were used to measure T-cell activation. In activated cells, CD44 expression is increased and CD62L expression is decreased. MLN cells were stained with anti-CD3-PE and anti-CD44-FITC antibodies (Becton Dickinson, Le pont de Claix, France). CD62L staining was done using a biotinylated anti-CD62L antibody, which was detected by a PE-cyanin7-Streptavidin conjugate (Becton Dickinson).
Statistical analysis
Statistical analysis was performed using the SAS package. The results are expressed as mean ± SD and comparison of different parameters among the groups was performed by using analysis of variance. The general linear model procedure was also used for multiple group-to-group comparisons. Because of a small number of mice in the placebo group, comparisons with this group were performed using non-parametric tests (Wilcoxon and Kruskal-Wallis). The differences were considered significant for p < 0.05.
Results
Body weight curves
Only slight and non-significant differences in the weight gain during the experimental protocol were noted among the groups (Fig. 1) . Rebamipide treatment did not modify the growth rate as compared to the control-and infected nontreated mice.
Microscopic score
The microscopic alterations (scores not exceeding 2) observed in the caecum and distal colon were mild in all mice groups, as summarized in Fig. 2 . In infected mice, the microscopic score in the distal colon was higher than in control mice (2.10 ± 1.29 vs. 0.82 ± 0.60, P < 0.01). No significant differences in microscopic score were observed between the . Infected mice presented a higher score than control mice. Treatment with rebamipide had no effect on histological score of colitis.
# P < 0.001 as compared to control mice mice treated with rectal rebamipide and the infected nontreated mice or placebo-treated mice.
Epithelial barrier function
Paracellular permeability
A reinforcement of the distal colonic barrier in mice treated with rebamipide enema was observed. This was attested by an increase in electrical resistance (R = 63 ± 25 /cm) and a decrease in mannitol fluxes (JMan = 57 ± 25 µmol/h.cm) as compared to the control mice (R = 40 ± 11 /cm, P < 0.05 and JMan = 117 ± 32 µmol/h.cm, P < 0.0005) and infected mice (R = 41 ± 11 /cm, P < 0.05 and JMan = 109 ± 43 µmol/h.cm, P < 0.003) (Fig. 3A) . In contrast, no significant differences in the parameters reflecting epithelial integrity were found in the caecum (R = 45 ± 8, 43 ± 11, 42 ± 15 and 51 ± 15 /cm, JMan = 68 ± 22, 55 ± 23, 53 ± 21 and 61 ± 18 µmol/h.cm, for the control, infected, rebamipide and placebo groups, respectively).
Macromolecular transport
A decrease in total (J 3 H-equivalent HRP)-and degraded (JD) -HRP fluxes across the distal colonic mucosa was found in mice treated with rebamipide (J 3 H-equivalent HRP = 1,012 ± 748 ng/h.cm, JD = 977 ± 758 ng/h.cm) as compared to the control mice (P < 0.01), infected mice (P < 0.01), and placebo mice (P < 0.05). Intact HRP fluxes (JHRPi) were not significantly different between the groups (JHRPi = 29.3 ± 24.7, 34.8 ± 30.0, 35 ± 36 and 17.2 ± 9.0 ng/h.cm, for control, infected, rebamipide and placebo groups, respectively) (Fig. 3B) . No significant differences were observed in HRP fluxes in the caecum among the groups (data not shown). * P < 0.05 as compared to control and infected; # P < 0.01 as compared to control and infected and P < 0.05 as compared to placebo
Activation status of mesenteric lymph node cells
Lymphocyte stimulation test as measured by 3 
H-thymidine incorporation
Under basal conditions, MLN cell proliferation increased in the rebamipide group (2,180 ± 2,661 3 H-cpm) as compared to the infected group (830 ± 830 3 H-cpm, P < 0.04), while no significant difference was found among the other groups (Fig. 4A ). After stimulation with soluble H. hepaticus antigens, there was again a significant increase in MLN cell proliferation in mice treated with rebamipide (4,027 ± 5,817 3 Hcpm) as compared to the control (1,503 ± 1,328 3 H-cpm, P < 0.05) and infected (1,193 ± 1,223 3 H-cpm, P < 0.03) mice (Fig. 4B) . This difference, however, was not found when results were expressed as stimulation indexes (1.09 ± 023, 1.33 ± 0.25, 1.33 ± 0.61 and 1.14 ± 0.16 in the control, infected, rebamipide and placebo groups, respectively, P>0.05), indicating that the basal and stimulated responses to H. hepaticus increased proportionally in the rebamipide group. No significant difference was observed (Fig. 5A) , there was a clear increase in IFNγ secretion by MLN cells in the rebamipide group (36.4 ± 93 pg/ml) as compared to the control (4.1 ± 13 pg/ml) and infected (2.9 ± 11 pg/ml) groups (P < 0.02). Similarly, rebamipide-treated mice presented a higher secretion of IL-12 (105 ± 90 pg/ml) than the infected mice (38 ± 38 pg/ml, P < 0.01). The basal IL-4 secretion achieved a higher level in the control mice (74 ± 77 pg/ml) than in all of the other groups (2.8 ± 7.8, 4.8 ± 4.0 and 4.8 ± 4.8 pg/ml for infected, rebamipide and placebo groups, respectively, P < 0.004). After stimulation with soluble H. hepaticus antigens (Fig. 5B) , a significant increase in IFNγ (148 ± 238 pg/ml) and IL-12 (239 ± 220 pg/ml) secretion was observed in the rebamipide group, as compared to all of the other groups, (P < 0.05). The IL-4 secretion remained the highest in the control mice (54.3 ± 47 pg/ml) in comparison to the infected mice (19.2 ± 25, P < 0.004) or placebotreated mice (0 ± 0, P < 0.01). After stimulation with soluble E. coli antigens, a similar increase in IFNγ secretion in the rebamipide group was observed (3,474 ± 3,289 pg/ml # P < 0.01 as compared to infected mice; § P < 0.004 as compared to all other groups; * * P < 0.05 as compared to all other groups; § § P < 0.02 as compared to infected and placebo groups versus 103 ± 169, 232 ± 383 and 57 ± 90 pg/ml, for the control, infected, and placebo groups, respectively, P < 0.0001).
IFN-γ secretion as measured by flow cytometry
The percentage of IFNγ -secreting MLN cells in basal conditions, measured by flow cytometry, is presented in Fig. 6 . A significant increase in both of the subsets, CD4 + and CD8 + , of T-cells secreting IFNγ was observed in mice treated with rebamipide enemas (IFNγ CD4 + : 6.1 ± 2.0% and IFNγ CD8 + : 4.1 ± 2.0%) as compared to the control group (IFNγ CD4 + : 1.2 ± 2.0% and IFNγ CD8 + : 0.76 ± 0.80%, P < 0.0001) and the infected group (IFNγ CD4 + : 1.1 ± 0.9% and IFNγ CD8 + : 0.46 ± 0.20%, P < 0.0001).
Expression of T-cell activation markers CD44 and CD62L as measured by flow cytometry No significant difference was found in the expression of CD44 and CD62L evaluated by flow cytometry (mean fluorescence intensity) among the four groups (CD44: 27.9 ± An increase in % of IFNγ -secreting CD4 + and CD8 + cells in rebamipide-treated mice was observed. * P < 0.0001 as compared to control and infected mice 8.5, 27.5 ± 10.2 and 22.9 ± 9.3 in the control, infected and rebamipide groups, respectively; CD62L: 20.7 ± 3.7, 27.4 ± 9.1 and 23.0 ± 4 in the control, infected and rebamipide groups, respectively).
Discussion
This study confirms the protective effect of rebamipide on the intestinal barrier, namely its capacity to reinforce the epithelial barrier capacity and to decrease the macromolecular transport across this barrier. At the same time, it demonstrates for the first time the immuno-stimulatory properties of rebamipide, which is capable of stimulating MLN cell proliferation and cytokine secretion.
The beneficial effect of rebamipide with respect to the epithelial barrier, already recognized for gastric and small intestinal mucosa [7, 17] , has now been shown for colonic mucosa. This effect concerns both paracellular and transcellular permeability. The fact that the improvement of barrier function observed after treatment with rebamipide enema was observed in the distal colon only, and not in the caecum, strongly points to the topical mechanism of action of rebamipide. The mechanism of its action on epithelial permeability, mostly studied in the stomach, is not completely understood. It could be related to rebamipide's capacity to act as a scavenger of cytokine-induced hydroxyl radicals [18] or to induce prostaglandin production [19] . A direct effect of the drug on the epithelial cells and/or inter-epithelial tight junctions could also play a role.
The protective effect of rebamipide on the colonic epithelial barrier and transepithelial protein absorption could account for its beneficial effect on a proctitis-type of ulcerative colitis in man [10] or dextran sulfate sodium-induced colitis in rats [9] . Indeed, in IBD, an increased epithelial permeability to luminal antigens can precede inflammatory lesions [20] and trigger mucosal inflammation. An increase in endosomal uptake of proteins, like HRP, in the histologically non-involved ileum of patients with CD, seems to be related to TNF-α expression [21] . Moreover, anti-TNF-α antibodies, infliximab, can restore the epithelial barrier alteration in CD [22] .
On the other hand, this study demonstrates the capacity of rebamipide to stimulate an immune response of MLN cells. This is attested by its capacity to induce MLN cell proliferation and also pro-inflammatory cytokines (IFNγ and IL-12) secretion by these cells, both under basal conditions and after stimulation with H. hepaticus. Taking into account the reinforcement of intestinal barrier by rebamipide, apparently associated with a decreased intestinal antigen, the higher proliferation of MLN cells in response to H. hepaticus antigens in rebamipide-treated mice is not easy to explain. It is possible, however, that specific immune response towards the infectious bacteria is increased, not due to the higher amount of infectious antigens crossing the epithelial barrier but rather to the lower threshold of the immune response by MLN cells induced by rebamipide. The rebamipide-enhanced cytokine secretion was demonstrated by ELISA and confirmed by flow cytometry. The lack of effect of rebamipide on the Tcell stimulation markers, CD44 and CD62L, suggests that these markers are less sensitive parameters of T-cell stimulation than cytokine secretion, at least in our model. The immuno-stimulatory properties of rebamipide observed in this study are in contrast to the previous studies where an inhibitory effect was observed on immune response, both in vitro [23] [24] [25] [26] [27] , and in vivo [9, [28] [29] [30] . This apparent contradiction may be explained by differences in the models used. In most of the studies cited above, the effect of rebamipide on immune response was tested under strong inflammatory conditions. In our experimental setting, the mice presented only a very slight colitis with histological scores reaching 2.0 at maximum, and low basal IFNγ and IL-12 secretion, which situates our model under sub-physiological conditions rather than pathological conditions. It is, therefore, possible that the effect of rebamipide observed in this study reflects an immunomodulatory effect similar to what is observed with probiotics, i.e., down-regulation under inflammatory conditions and up regulation under physiological conditions [31] [32] [33] [34] [35] [36] . It is also possible that the known down-regulatory effect of rebamipide on immune response does not appear in this model of IL-10-deficient mice because the drug may need IL-10 to reveal this effect. Indeed, rebamipide has been shown to strongly inhibit IL-10 secretion by human peripheral blood mononuclear cells in vitro [23] . On the other hand, it is important to point out that the maximal increase in IFNγ secretion induced by rebamipide in this study (4 ng/ml), was lower than the concentration necessary to significantly damage the epithelial barrier (10 ng/ml), as assessed in vitro [37] . In fact, our results showed that rebamipide-treated mice presented a reinforcement of the intestinal barrier as compared to the other groups. This indicates that the relative increase in IFNγ secretion induced by rebamipide had no deleterious effect on the barrier.
A slight stimulation of Th-1 immune response by rebamipide in this model of Th1-mediated colitis in IL-10 knock-out mice should logically be associated with exacerbation of colitis. However, no difference was observed in this study in the degree of colitis between rebamipide-treated and non-treated mice. This may be related, on one hand, to the generally low degree of colitis observed in all mice, not allowing to see any significant differences in colitis score among the groups and, on the other hand, to the relatively low degree of stimulation of Th-1 response by revamped, as mentioned above.
It is conceivable that this slight stimulation of Th1-type immune response by rebamipide may counteract Th2 immune responses. This could explain the beneficial effect of rebamipide described in proctitis-type of ulcerative colitis in man [10] , a disease associated with Th2-stimulation [38, 39] . Clinical studies are necessary to confirm this hypothesis.
We did not observe any effect of rebamipide on colonic histology. This may again be related to the low degree of inflammation obtained in all animals, not allowing evidencing any difference between treated and non-treated mice. Indeed, the model of IBD in IL-10-deficient mice that we chose is highly susceptible to environmental factors (housing, food) and genetic factors (mice strains) [40] . Although Kullberg et al. published several studies where inflammation was increased in the presence of H. hepaticus [13] , other authors have failed to induce a marked colitis in these mice even after colonization with H. hepaticus [41] .
In conclusion, this study shows that under sub-normal conditions of mild colitis, rectally administered rebamipide exerts a direct beneficial effect on the large bowel epithelial barrier integrity and function. It restrains the paracellular pathway and decreases protein absorption across the barrier. It also reveals an immuno-stimulatory effect on mesenteric lymph node cells, stimulating secretion of Th1-type cytokines, IFNγ and IL-12. This improvement of the intestinal barrier, together with the capacity of rebamipide to modulate immune responses, may be a new therapeutic approach potentially useful in the clinical management of IBD, especially those associated with Th2-stimulation like ulcerative colitis. Future clinical studies are necessary to test its utility in such a group of patients.
